Print PDF
Axinn's Chad Landmon Discusses the Likelihood of the FTC Increasing Efforts to Obtain Passage of "Pay-For-Delay" Legislation with Drug Industry Daily
February 25, 2010

During the last week of February, the U.S. District Court for the Northern District of Georgia dismissed multidistrict litigation filed by the FTC and direct and indirect purchasers that claimed reverse payment, or “pay-for-delay,” settlements Solvay Pharmaceuticals made with Watson Pharmaceuticals, Par Pharmaceutical and Paddock Laboratories for the marketing of generic AndroGel violated federal antitrust laws. Chad Landmon told Drug Industry Daily on February 25th that “the decision could lead to a louder voice from FTC and others in favor of legislation, pointing to this decision as another example of courts ruling in favor of these settlements.”  Landmon also noted that the decision is a “pretty strong decision in favor of pharmaceutical companies.”  

The article is entitled, "Drugmakers Score Pay-for-Delay Victory Against FTC," Drug Industry Daily, February 25, 2010, FDAnews 300 N. Washington St., Suite 200, Falls Church, VA 22046

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.